Phase I Study of Nimotuzumab in Solid Tumours

NCT00369252 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced and/or Metastatic Solid Tumours

Interventions

DRUG: Nimotuzumab (TheraCIM h-R3)

Sponsor

YM BioSciences

Collaborators

[object Object]